Aclaris Therapeutics (ACRS) Retained Earnings (2014 - 2026)

Aclaris Therapeutics' Retained Earnings history runs 13 years deep, the most recent figure standing at -$987.6 million for Q1 2026.

• On a quarterly basis, Retained Earnings fell 193.03% year-over-year to -$987.6 million in Q1 2026; TTM through Mar 2026 was -$987.6 million, a 193.03% decrease from a year earlier, with the FY2025 full-year figure at -$967.8 million, down 997815.46% from the prior year.
• Retained Earnings slipped to -$987.6 million in Q1 2026 per ACRS's latest filing, from -$967.8 million in the prior quarter.
• Across five years, Retained Earnings topped out at $1.1 billion in Q2 2025 and bottomed at -$987.6 million in Q1 2026.
• The 5-year median for Retained Earnings is -$1.1 million (2023), against an average of -$47.5 million.
• Across the five-year window, Retained Earnings jumped 103564.88% in 2023 and tumbled 997815.46% in 2025, its largest moves.
• Year by year, Retained Earnings stood at -$897000.0 in 2022, then soared by 103564.88% to $928.1 million in 2023, then tumbled by 99.99% to $97000.0 in 2024, then tumbled by 997815.46% to -$967.8 million in 2025, then dropped by 2.05% to -$987.6 million in 2026.
• Per Business Quant, the three latest ACRS Retained Earnings figures stand at -$987.6 million (Q1 2026), -$967.8 million (Q4 2025), and -$948.0 million (Q3 2025).